Therapeutic vaccination against human papillomavirus type 16 for the treatment of anal intraepithelial neoplasia in HIV+ men

Trial Profile

Therapeutic vaccination against human papillomavirus type 16 for the treatment of anal intraepithelial neoplasia in HIV+ men

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs ISA 101 (Primary) ; Peginterferon alfa-2a
  • Indications Anal cancer; Anal intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VACCAIN-T
  • Sponsors ISA Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Aug 2016 Planned End Date changed from 1 Feb 2018 to 1 Jan 2018.
    • 05 Aug 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top